Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. (HRMY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hrmy · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Harmony Biosciences Holdings, Inc. (HRMY) measures how much investors pay for each dollar of the company's trailing earnings. HRMY's current PE ratio of 12.79x is calculated by dividing its stock price of $32.36 by its TTM earnings per share of $2.52. −51.1% discount vs 5Y avg 26.2x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 5 fiscal years · Front-end computedMinQ1 · 25%14.9x
MedianQ3 · 75%70.9x
Max
At 12.79x, HRMY's current P/E is lower than in 0% of its annual fiscal year readings over the past 5 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Harmony Biosciences Holdings, Inc.You HRMY | $1.9B | 12.79x | — | $2.52 |
 AbCellera Biologics Inc. ABCL | $1.7B | N/A | — | -$0.49 |
 Aurinia Pharmaceuticals Inc. AUPH | $2.0B | 7.46x | — | $2.14 |
 Biohaven Ltd. BHVN | $1.1B | N/A | — | -$6.86 |
 Celldex Therapeutics, Inc. CLDX | $1.9B | N/A | — | -$3.89 |
 Immunocore Holdings plc IMCR | $1.4B | N/A | — | -$0.52 |
 Janux Therapeutics, Inc. JANX | $815M | N/A | — | -$1.83 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 13.56x | $2.76 | +0.8% | |
2024-12-31 FY2024 | 13.45x | $2.56 | -9.8% | |
2023-12-31 FY2023 | 14.91x | $2.17 | -17.0% | |
2022-12-31 FY2022 | 17.97x | $3.07 | -74.7% | |
2021-12-31 FY2021 | 70.91x | $0.60 | — | |
2020-12-31 FY2020 | — | $-0.65 | — | |
2019-12-31 FY2019 | — | $-2.39 | — | |
2018-12-31 FY2018 | — | $-0.81 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Harmony Biosciences Holdings, Inc. (HRMY) measures how much investors pay for each dollar of the company's trailing earnings. HRMY's current PE ratio of 12.79x is calculated by dividing its stock price of $32.36 by its TTM earnings per share of $2.52.
Frequently asked questions
HRMY pe ratio · 6 questionsHRMY's current PE ratio is 12.79x as of 2026-06-08, based on a stock price of $32.36 and TTM EPS of $2.52. Data sourced from Financial Modeling Prep via HRMY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Harmony Biosciences Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08